test | True prevalence | Apparent prevalence |
---|
BBA-TOX | 56.6% | 50.1% |
E1-TOX | Â | 38.3% |
E2-TOX | Â | 45.9% |
E3-TOX | Â | 48.0% |
BBA-TRI | 58.6% | 39.8% |
E-TRI | Â | 44.2% |
- BBA-TOX, T. gondii antigen coupled bead-based assay; E1-TOX, RIVM in-house T. gondii ELISA; E2-TOX, Safepath T. gondii ELISA; E3-TOX, ID-VET T. gondii ELISA; BBA-TRI, T. spiralis antigen coupled bead-based assay and E-TRI, Safepath T. spiralis ELISA